Article: Gen-Probe Does Not Intend to Increase Offer to Acquire Innogenetics.

SAN DIEGO, July 9 /PRNewswire/ --

Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company does not intend to increase the value of its conditional tender offer to acquire 100% of the outstanding shares, warrants and convertible bonds of Innogenetics (EBR: INNX), a Belgian molecular diagnostics company.

"We believe the disciplined analytical process we used to value Innogenetics resulted in a full and fair offer, and a higher bid therefore does not make financial sense for us," said Hank Nordhoff, Gen-Probe's chairman and chief executive officer. "Our existing clinical diagnostics and blood screening businesses remain healthy year-to-date, and we ...

Related newspaper, magazine, and journal articles:

No articles like the one above were found.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!